Gilead
-
{
- All
- News
- Videos
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
WHO Removes Remdesivir From List Of Medicines Used As Benchmark
The World Health Organization said on Friday it has suspended Gilead's remdesivir from its so-called prequalification list, an official list of medicines used as a benchmark for procurement by developing countries, after issuing guidance against its use in hospitalised COVID-19 patients.
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
Fight Against COVID-19 Clearest Example Of US-India Partnership: US Official
India and the US are equipped to address a range of challenges for the benefit of the world and the clearest example of this can be seen in the partnership between the two countries to fight the COVID-19 pandemic, a senior State Department official has said.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
-
Remdesivir Reduces Risk Of Death In COVID-19 Patients, Says Gilead
Gilead Sciences Inc. said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
Astronomers Discover Two Super-Earths Orbiting a Star 11 Light-Years Away
Astronomers have discovered two super-Earths around a star Gilese 887 that is approximately 11 light-years away from our planet. The two exoplanets – a term used for planets outside our solar system – are called Gilese 887b and Gilese 887c, and the scientists claim that they could ‘potentially host life’.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
Gilead's Drug Prevents Lung Damage In COVID-19 Study On Monkeys: Report
Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaque monkeys infected with the new coronavirus, a study published in medical journal Nature showed on Tuesday.
-
Gilead's Remdesivir Shows Fair Improvement In Moderate COVID-19 Patients
Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received the medicine for 10 days in the study did not fare as well.
-
Gilead Trades That Made Millions On COVID-19 Drug News Under Scrutiny
Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
-
Health Groups Ask India To Rescind Gilead's Patents For COVID-19 Drug
Two health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations.
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
WHO Removes Remdesivir From List Of Medicines Used As Benchmark
The World Health Organization said on Friday it has suspended Gilead's remdesivir from its so-called prequalification list, an official list of medicines used as a benchmark for procurement by developing countries, after issuing guidance against its use in hospitalised COVID-19 patients.
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
Fight Against COVID-19 Clearest Example Of US-India Partnership: US Official
India and the US are equipped to address a range of challenges for the benefit of the world and the clearest example of this can be seen in the partnership between the two countries to fight the COVID-19 pandemic, a senior State Department official has said.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
-
Remdesivir Reduces Risk Of Death In COVID-19 Patients, Says Gilead
Gilead Sciences Inc. said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
Astronomers Discover Two Super-Earths Orbiting a Star 11 Light-Years Away
Astronomers have discovered two super-Earths around a star Gilese 887 that is approximately 11 light-years away from our planet. The two exoplanets – a term used for planets outside our solar system – are called Gilese 887b and Gilese 887c, and the scientists claim that they could ‘potentially host life’.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
Gilead's Drug Prevents Lung Damage In COVID-19 Study On Monkeys: Report
Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaque monkeys infected with the new coronavirus, a study published in medical journal Nature showed on Tuesday.
-
Gilead's Remdesivir Shows Fair Improvement In Moderate COVID-19 Patients
Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received the medicine for 10 days in the study did not fare as well.
-
Gilead Trades That Made Millions On COVID-19 Drug News Under Scrutiny
Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
-
Health Groups Ask India To Rescind Gilead's Patents For COVID-19 Drug
Two health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations.
